Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.

[1]  K. Berka,et al.  2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro. , 2015, Bioorganic & medicinal chemistry letters.

[2]  S. Rault,et al.  Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series. , 2015, Bioorganic & medicinal chemistry.

[3]  J. Sangshetti,et al.  Antileishmanial drug discovery: comprehensive review of the last 10 years , 2015 .

[4]  Vijay Luxami,et al.  Recent advances in development of imidazo[1,2-a]pyrazines: synthesis, reactivity and their biological applications. , 2015, Organic & biomolecular chemistry.

[5]  V. Kaplum,et al.  Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents. , 2015, European journal of medicinal chemistry.

[6]  F. Supek,et al.  Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis , 2014, Chemical reviews.

[7]  Kenneth Stuart,et al.  Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites , 2014, Chemical reviews.

[8]  S. Gibbons,et al.  Fruitful decade for antileishmanial compounds from 2002 to late 2011. , 2014, Chemical reviews.

[9]  A. Megens,et al.  Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia. , 2014, Journal of medicinal chemistry.

[10]  Xufeng Cao,et al.  Design , Synthesis , and Structure − Activity Relationship Studies of Novel Fused Heterocycles-Linked Triazoles with Good Activity and Water Solubility , 2014 .

[11]  Malcolm P. Huestis,et al.  Sequential C3 and C5 Direct C–H Arylation of Imidazo[1,2‐a]pyrazines with (Hetero)aryl Bromides , 2014 .

[12]  Nisha Singh,et al.  Natural product based leads to fight against leishmaniasis. , 2014, Bioorganic & medicinal chemistry.

[13]  L. Meijer,et al.  Pharmacological Assessment Defines Leishmania donovani Casein Kinase 1 as a Drug Target and Reveals Important Functions in Parasite Viability and Intracellular Infection , 2013, Antimicrobial Agents and Chemotherapy.

[14]  C. Jaffe,et al.  Identification of a Secreted Casein Kinase 1 in Leishmania donovani: Effect of Protein over Expression on Parasite Growth and Virulence , 2013, PloS one.

[15]  M. Bazin,et al.  Exploration of versatile reactions on 2-chloro-3-nitroimidazo[1,2-a]pyridine: expanding structural diversity of C2- and C3-functionalized imidazo[1,2-a]pyridines , 2013 .

[16]  L. Meijer,et al.  Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents. , 2012, European journal of medicinal chemistry.

[17]  D. Rotella.  Recent results in protein kinase inhibition for tropical diseases. , 2012, Bioorganic & medicinal chemistry letters.

[18]  Nisha Singh,et al.  Leishmaniasis: current status of available drugs and new potential drug targets. , 2012, Asian Pacific journal of tropical medicine.

[19]  I. Grekov,et al.  Leishmaniasis: prevention, parasite detection and treatment. , 2012, Current medicinal chemistry.

[20]  M. Bazin,et al.  An efficient access to 2,3-diarylimidazo[1,2-a]pyridines via imidazo[1,2-a]pyridin-2-yl triflate through a Suzuki cross-coupling reaction-direct arylation sequence , 2012 .

[21]  Ian H Gilbert,et al.  Identification of Inhibitors of the Leishmania cdc2-Related Protein Kinase CRK3 , 2011, ChemMedChem.

[22]  C. Nakamura,et al.  Recent advances in leishmaniasis treatment. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[23]  M. Walkinshaw,et al.  Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines. , 2011, Bioorganic & medicinal chemistry letters.

[24]  P. Pescher,et al.  Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation , 2011, Cellular microbiology.

[25]  S. Antinori,et al.  Leishmaniasis: new insights from an old and neglected disease , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[26]  M. Yadav,et al.  Antileishmanial Agents: An Updated Review , 2011 .

[27]  C. G. Mohan,et al.  Mitogen-activated protein kinase 4 of Leishmania parasite as a therapeutic target. , 2010, European journal of medicinal chemistry.

[28]  A. Addlagatta,et al.  Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines. , 2010, European journal of medicinal chemistry.

[29]  J. Aponte,et al.  Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. , 2010, Bioorganic & medicinal chemistry.

[30]  V. Dubey,et al.  Rational Approaches for Drug Designing Against Leishmaniasis , 2010, Applied biochemistry and biotechnology.

[31]  A. Choudhary,et al.  Leishmaniasis: current treatment strategies and future opportunities. , 2010 .

[32]  P. Le Pape,et al.  Infectivity of Leishmania mexicana Is Associated with Differential Expression of Protein Kinase C-Like Triggered during a Cell-Cell Contact , 2009, PloS one.

[33]  P. Pescher,et al.  Leishmania major MPK7 Protein Kinase Activity Inhibits Intracellular Growth of the Pathogenic Amastigote Stage , 2009, Eukaryotic Cell.

[34]  Suman Gupta,et al.  Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents. , 2009, Bioorganic & medicinal chemistry letters.

[35]  David Lapointe,et al.  Establishment of broadly applicable reaction conditions for the palladium-catalyzed direct arylation of heteroatom-containing aromatic compounds. , 2009, The Journal of organic chemistry.

[36]  C. Musonda,et al.  Synthesis and evaluation of 2-pyridyl pyrimidines with in vitro antiplasmodial and antileishmanial activity. , 2009, Bioorganic & medicinal chemistry letters.

[37]  K. Grant.  Targeting the cell cycle in the pursuit of novel chemotherapies against parasitic protozoa. , 2008, Current pharmaceutical design.

[38]  J. Galy,et al.  Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine. , 2007, European journal of medicinal chemistry.

[39]  M. Wiese.  Leishmania MAP kinases--familiar proteins in an unusual context. , 2007, International journal for parasitology.

[40]  L. Meijer,et al.  Purification of CK1 by affinity chromatography on immobilised axin. , 2007, Protein expression and purification.

[41]  H. Gornitzka,et al.  Spirolactone iridoids might be responsible for the antileishmanial activity of a Peruvian traditional remedy made with Himatanthus sucuuba (Apocynaceae). , 2007, Journal of ethnopharmacology.

[42]  B. Nare,et al.  Inhibitors of casein kinase 1 block the growth of Leishmania major promastigotes in vitro. , 2006, International journal for parasitology.

[43]  P. Le Pape,et al.  Antileishmanial activities and mechanisms of action of indole-based azoles , 2006, Journal of enzyme inhibition and medicinal chemistry.

[44]  Lin Tang,et al.  Roscovitine Targets, Protein Kinases and Pyridoxal Kinase*[boxs] , 2005, Journal of Biological Chemistry.

[45]  B. Tekwani,et al.  Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues. , 2005, Bioorganic & medicinal chemistry.

[46]  P. Le Pape,et al.  Synthesis and Antileishmanial Activity of 3-(α-Azolylbenzyl)indoles , 2002 .

[47]  F. Pagniez,et al.  A new automatized fluorometric assay for anti-Leishmania drug screening , 2002 .

[48]  N. Goyal,et al.  In vitro cultivation and characterization of axenic amastigotes of Leishmania. , 2001, Trends in parasitology.

[49]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[50]  D. Sereno,et al.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents , 1997, Antimicrobial agents and chemotherapy.

[51]  D. Sereno,et al.  Use of an enzymatic micromethod to quantify amastigote stage of Leishmania amazonensis in vitro , 1997, Parasitology Research.